PALO ALTO, Calif., April 4, 2016 /PRNewswire/ -- Inscopix Inc., today announced the commercial launch of its nVista brain imaging platform to the neuroscience research community. Centered on a patented miniature microscope technology from Stanford University, the nVista system is a significant technological advance that decodes the neural language underlying brain function and behavior. Originally only accessible through the Neuroscience Early Access Program (NEAP), Inscopix plans to expand the reach of nVista to the widest spectrum of neuroscience investigators through packages customized for specific researcher needs.
"As we draw the curtains on NEAP for nVista with its commercial launch, we are immensely grateful to the NEAP labs who took a chance on a young company and a new technology," said Kunal Ghosh, Inscopix founder and CEO. "Thanks to their collaboration, we now have a much richer offering that goes beyond instrumentation to include surgical tools, data analytics, scientific support, and training. Looking ahead, we are truly excited about the magnitude of scientific breakthroughs that will continue to be enabled by nVista, now that we are opening access to the entire neuroscience research community."
Since the launch of NEAP in 2012, Inscopix disseminated nVista to over 100 early-adopter labs that played a crucial role in maturing the platform through feedback and scientific validation for its incorporation into standard neuroscience practice. NEAP researchers have published close to 20 research articles with nVista in top tier journals such as Neuron, Nature, and Cell, that provided deeper insights into multiple aspects of brain function, including motivation, learning and memory, and goal-directed behaviors. nVista also led to Inscopix's recognition by the World Economic Forum as a "Technology Pioneer" in 2015.
Inscopix is a discovery-phase neuroscience company in Palo Alto, CA, that develops integrated solutions for understanding the brain in action. Inscopix serves its clients in over a hundred academic and neuropharmaceutical research laboratories through its flagship brain imaging product, nVista, data analytics suite, Mosaic, and training workshops. Inscopix is pursuing a rigorous science-centric approach to technological innovation, creating unprecedented opportunities to advance fundamental brain research and the development of treatments for brain disorders such as Alzheimer's disease, schizophrenia, and autism.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inscopix-exits-early-access-phase-to-publicly-launch-end-to-end-platform-for-imaging-neural-circuit-activity-300245961.html
SOURCE Inscopix Inc.